Literature DB >> 11740737

Heterologous neutralizing antibody induction in a simian-human immunodeficiency virus primate model: lack of original antigenic sin.

R A Rasmussen1, D C Montefiori, H L Robinson, H M McClure, R M Ruprecht.   

Abstract

According to the principle of original antigenic sin, neutralizing antibodies (NAbs) initially directed against a single virus strain compromise the immune system's ability to subsequently mount adequate responses against antigenically divergent virus strains. In this study, rhesus macaques, after vaccination and breakthrough infection with homologous simian-human immunodeficiency virus (SHIV), developed strong SHIV-IIIB strain-directed NAb responses that were mostly V3 loop specific. After superinfection with heterologous SHIV89.6P, all macaques developed high-titer SHIV89.6P-specific NAbs without significant boosting of SHIV-IIIB-specific NAbs. These results indicate that prior B cell responses against a single immunodeficiency virus strain do not preclude the later development of NAbs against a divergent strain of the same virus.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11740737     DOI: 10.1086/324582

Source DB:  PubMed          Journal:  J Infect Dis        ISSN: 0022-1899            Impact factor:   5.226


  6 in total

Review 1.  No acquisition: a new ambition for HIV vaccine development?

Authors:  Samir K Lakhashe; Guido Silvestri; Ruth M Ruprecht
Journal:  Curr Opin Virol       Date:  2011-10       Impact factor: 7.090

2.  Sequential immunization with a subtype B HIV-1 envelope quasispecies partially mimics the in vivo development of neutralizing antibodies.

Authors:  Delphine C Malherbe; Nicole A Doria-Rose; Lynda Misher; Travis Beckett; Wendy Blay Puryear; Jason T Schuman; Zane Kraft; Jean O'Malley; Motomi Mori; Indresh Srivastava; Susan Barnett; Leonidas Stamatatos; Nancy L Haigwood
Journal:  J Virol       Date:  2011-03-23       Impact factor: 5.103

3.  Bimodal AIDS vaccine approach: induction of cellular as well as humoral immunity can protect from systemic infection.

Authors:  Robert A Rasmussen; Samir K Lakhashe; Ruth M Ruprecht
Journal:  Vaccine       Date:  2010-05-26       Impact factor: 3.641

4.  SHIV infection protects against heterologous pathogenic SHIV challenge in macaques: a gold-standard for HIV-1 vaccine development?

Authors:  Robert Sealy; Xiaoyan Zhan; Timothy D Lockey; Louis Martin; James Blanchard; Vicki Traina-Dorge; Julia L Hurwitz
Journal:  Curr HIV Res       Date:  2009-09       Impact factor: 1.581

5.  Live-virus exposure of vaccine-protected macaques alters the anti-HIV-1 antibody repertoire in the absence of viremia.

Authors:  Barbara C Bachler; Michael Humbert; Samir K Lakhashe; Robert A Rasmussen; Ruth M Ruprecht
Journal:  Retrovirology       Date:  2013-06-21       Impact factor: 4.602

6.  The aftermath of the Merck's HIV vaccine trial.

Authors:  Enrico Iaccino; Marco Schiavone; Giuseppe Fiume; Ileana Quinto; Giuseppe Scala
Journal:  Retrovirology       Date:  2008-07-02       Impact factor: 4.602

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.